Loading patent…
AssigneesGarvan Institute of Medical Research, Amelgo, LLC
InventorsChris ORMANDY, Samantha OAKES, Nelson HORSEMAN
Estimating the term…
The disclosure relates generally to methods and reagents for reducing or shutting down lactation in a non-human mammalian subject. In particular, the disclosure relates to a method of reducing or shutting down lactation in a non-human mammalian subject by administering to the subject by intramammary infusion an agent which activate the OAS2 signalling pathway or induce expression of OAS2. In some examples, the methods and reagents of the disclosure may be useful for the prevention of mastistis in a non-human mammalian subject, such as a dairy cow.
A method of reducing or shutting down lactation in a non-human mammalian subject, said method comprising administering to the mammary gland of the subject an agent which activates the OAS2 signalling pathway or induces expression of OAS2 in the mammary gland of the subject.
An intramammary veterinary composition comprising an agent which activates the OAS2 signalling pathway or induces expression of OAS2 in the mammary gland of a non-human mammalian subject and a pharmaceutically acceptable excipient or carrier, wherein the agent is present in an amount sufficient to reduce or shut down lactation in the non-human mammalian subject.
Use of an agent which activates the OAS2 signalling pathway or induces expression of OAS2 in the preparation of a medicament for reducing or shutting down lactation in a non-human mammalian subject in need thereof.
Use of an agent which activates the OAS2 signalling pathway or induces expression of OAS2 in the preparation of a medicament for preventing mastitis in a non-human mammalian subject which is lactating and not suffering from mastitis.
Dependencies are inferred from the claim text.